CoChat

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

Dobbins, R. L., O’Connor‐Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., Hussey, E. K. · 2012 · Diabetes, Obesity and Metabolism
Cited by 79

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aims: Remogliflozin etabonate (RE) is the pro‐drug of remogliflozin (R), a selective inhibitor of renal sodium‐dependent glucose transporter 2 (SGLT2) that improves glucose control via enhanced urinary glucose excretion (UGE). This study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of RE in subjects with type 2 diabetes mellitus (T2DM). Methods: In a double‐blinded, randomized, placebo‐controlled trial, subjects who were drug‐naïve or had metformin discontinued received RE [100 mg BID (n = 9), 1000 mg QD (n = 9), 1000 mg BID (n = 9)], or placebo (n = 8) for 12 days. Safety parameters were assessed, including urine studies to evaluate renal function. Plasma concentrations of RE and metabolites were measured with the first dose and at steady state. RE effects on glucose levels were assessed with fasting glucose concentrations, frequently sampled 24‐h glucose profiles and oral glucose tolerance tests. Results: No significant laboratory abnormalities or safety events were reported; the most frequent adverse events were headache and flatulence. Plasma exposure to RE and R were proportional to administered dose with negligible accumulation. Mean 24‐h UGE increased in RE treatment groups. Compared with the placebo group, 24‐h mean (95% CI) changes in plasma glucose were −1.2 (−2.2 to −0.3) (100 mg BID), −0.8 (−1.7 to 0.2) (1000 mg QD) and −1.7 (−2.7 to −0.8) mmol/l (1000 mg BID). Conclusions: Administration of RE for 12 days is well‐tolerated and results in clinically meaningful improvements in plasma glucose, accompanied by changes in body weight and blood pressure in subjects with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01462.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 79

Metadata

Authors
Dobbins, R. L., O’Connor‐Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., & Hussey, E. K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-10-30
Volume
14
Issue
1
Pages
15-22
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2123549473
Cited by
79
References
4
FWCI
8.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01462.x
The paper
Dobbins, R. L., O’Connor‐Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., & Hussey, E. K. (2012). Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01462.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.